Oura sues rival Ultrahuman again, threatening its U.S. smart ring comeback

Oura sued Ultrahuman in Texas, alleging its Ring Pro infringes two patents and seeking monetary damages and a permanent U.S. sales injunction; the suit also names manufacturer SVTronics. The case follows an earlier import ban on Ultrahuman’s Ring Air and comes after Customs allowed the redesigned Ring Pro back into the U.S. Oura shelved its planned $2.2 billion IPO weeks ago, while IDC expects smart-ring shipments to grow 12.8% this year to 4.9 million units and reach about 6.3 million by 2030.

Analysis

The important read-through is not near-term unit growth but whether Oura can turn IP into a toll on the category. A durable injunction or credible licensing threat could redirect U.S. demand toward Oura and raise competitors’ costs; it could also make smart rings less attractive to launch, slowing category expansion and ultimately limiting Oura’s own addressable market. RingConn and Circular’s licensing outcomes suggest a commercial settlement is possible, but do not establish that these newly asserted patents are valid or cover Ring Pro.

The new patent’s timing creates both leverage and litigation risk: the case may pressure Ultrahuman before it builds U.S. distribution, yet patent scope, validity, and infringement remain untested. A redesign or license would blunt the disruption; a court finding against Oura would weaken its broader deterrence strategy. Over the next 1–3 months, watch for an injunction request, court schedule, and any redesign or settlement. Over 6–18 months, the key question is whether enforcement produces recurring royalties or merely legal expense and uncertainty. Either outcome may influence how Samsung, Zepp Health, and other entrants price IP risk.

For OURA, stronger exclusivity could support strategic value, but unresolved litigation is also a diligence and timing overhang for any future IPO. Qualcomm’s exposure is indirect: Ultrahuman disruption could impair its investment or collaboration optionality, while a successful product partnership could still have strategic value. Labcorp’s exposure cannot be sized from the disclosed information. No clean directional equity trade is supported without valuation, ownership, and case-probability data.

Key Decisions for Investors

• No immediate directional trade: treat OURA as a litigation catalyst watch, not a proven earnings inflection. Verify the requested relief, likelihood and timing of preliminary injunctive action, and whether the asserted claims survive validity challenges before underwriting a U.S. share shift.
• For the next 1–3 months, monitor docket developments and any settlement, license, or redesign. A negotiated license would be less disruptive to category growth than an injunction, while still potentially supporting Oura’s IP monetization thesis.
• Keep QCOM exposure on alert rather than changing the position: determine the size and terms of its Ultrahuman investment and the scope of the collaboration before attributing material downside. Reassess if Ultrahuman’s U.S. commercialization or the joint product timeline is demonstrably impaired.
• Falsifiers for the Oura-enforcement thesis: denial of meaningful injunctive relief, invalidation or narrow construction of the new patent claims, or continued Ring Pro U.S. sales without a license. Evidence of recurring royalties across competitors would strengthen the longer-term moat case.